Generic medicine

Infliximab: Brands, Price & Uses in Bangladesh

Infliximab is a chimeric monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-alpha), administered by intravenous infusion for a range of chronic inflammatory and autoimmune conditions.

Forms:Injection

About Infliximab

Indications of Infliximab

Infliximab is a chimeric monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-alpha), administered by intravenous infusion for a range of chronic inflammatory and autoimmune conditions. Its uses are classified below by strength of evidence.

Established / FDA-Approved Uses

  • Rheumatoid arthritis: Moderate-to-severe active rheumatoid arthritis, in combination with methotrexate, to reduce signs and symptoms, inhibit progression of structural damage, and improve physical function.
  • Crohn's disease (adult and pediatric): Moderately-to-severely active Crohn's disease with an inadequate response to conventional therapy, and fistulizing Crohn's disease, to reduce the number of draining fistulas and maintain fistula closure.
  • Ulcerative colitis (adult and pediatric): Moderately-to-severely active ulcerative colitis with an inadequate response to conventional therapy.
  • Ankylosing spondylitis: Active ankylosing spondylitis, to reduce signs and symptoms.
  • Psoriatic arthritis: Active psoriatic arthritis, to reduce signs and symptoms of active arthritis and inhibit progression of structural damage.
  • Plaque psoriasis: Chronic severe (extensive and/or disabling) plaque psoriasis in adults who are candidates for systemic therapy.

Important Notes

  • For rheumatoid arthritis, Infliximab must be given in combination with methotrexate; it is not indicated as monotherapy for this indication.
  • Infliximab is generally reserved for patients who have had an inadequate response to conventional (non-biologic) therapy.

Dosage & Administration of Infliximab

Adult Dose (by indication)

IndicationInduction DoseMaintenance Dose
Rheumatoid arthritis (with methotrexate)3 mg/kg IV at weeks 0, 2, and 63 mg/kg every 8 weeks; may increase up to 10 mg/kg or shorten interval to every 4 weeks if response is inadequate
Crohn's disease / fistulizing Crohn's disease5 mg/kg IV at weeks 0, 2, and 65 mg/kg every 8 weeks
Ulcerative colitis5 mg/kg IV at weeks 0, 2, and 65 mg/kg every 8 weeks
Ankylosing spondylitis5 mg/kg IV at weeks 0, 2, and 65 mg/kg every 6 weeks
Psoriatic arthritis5 mg/kg IV at weeks 0, 2, and 65 mg/kg every 8 weeks
Plaque psoriasis5 mg/kg IV at weeks 0, 2, and 65 mg/kg every 8 weeks

Pediatric Dose

For pediatric Crohn's disease (age 6 years and older) and pediatric ulcerative colitis (age 6 years and older): 5 mg/kg IV at weeks 0, 2, and 6, then every 8 weeks thereafter, in combination with conventional therapy as appropriate. Safety and efficacy have not been established in children younger than 6 years for these indications, and Infliximab is not established for pediatric rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or plaque psoriasis (see Pediatric Uses).

Renal / Hepatic Impairment

Infliximab has not been formally studied in patients with renal or hepatic impairment, and no specific dose adjustment has been established; use with clinical judgment and monitoring. Infliximab should not be initiated in patients with active hepatic dysfunction, and therapy should be discontinued if new or worsening significant liver injury develops.

Administration

Infliximab must be administered only by a qualified healthcare professional as an intravenous infusion over at least 2 hours, using an in-line, low-protein-binding filter, in a setting equipped to manage infusion reactions and anaphylaxis. It must never be given as an intravenous push or bolus, and it is not for subcutaneous, intramuscular, or self-administered home use.

Side Effects of Infliximab

The most commonly reported side effects of Infliximab include:

  • Infusion-related reactions (fever, chills, itching, hives, chest pain, hypotension or hypertension, shortness of breath)
  • Upper respiratory tract infections and sinusitis
  • Headache
  • Abdominal pain and nausea
  • Cough
  • Rash
  • Fatigue

Serious but less common effects include serious infections (including reactivation of tuberculosis and hepatitis B), malignancies including lymphoma, heart failure exacerbation, demyelinating neurologic disease, lupus-like syndrome, and severe hepatic reactions (see Precautions and Warnings). Patients should seek prompt medical attention for signs of infection, unusual bruising or bleeding, jaundice, chest pain, or severe allergic reaction while receiving Infliximab.

Contraindications of Infliximab

Infliximab is contraindicated in:

  • Patients with known hypersensitivity to Infliximab, to any other murine (mouse-derived) proteins, or to any component of the formulation.
  • Patients requiring doses greater than 5 mg/kg who have moderate-to-severe heart failure (NYHA Class III/IV).
  • Patients with an active, serious infection, including active tuberculosis, sepsis, abscesses, or opportunistic infections.

Frequently Asked Questions about Infliximab

What is Infliximab used for?

Infliximab is a biologic medicine used to treat several chronic inflammatory and autoimmune conditions, including moderate-to-severe rheumatoid arthritis (with methotrexate), Crohn's disease (including fistulizing disease), ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis. It works by blocking a protein called TNF-alpha that drives inflammation in these diseases.

How is Infliximab given?

Infliximab is given only by a healthcare professional as a slow intravenous (IV) infusion, usually over at least 2 hours, in a clinic or hospital setting equipped to manage allergic or infusion reactions. It is not a tablet or injection you give yourself at home. Treatment usually starts with infusions at weeks 0, 2, and 6, followed by a maintenance infusion every 4 to 8 weeks.

Why do I need testing before starting Infliximab?

Before starting Infliximab, your doctor will screen you for tuberculosis (TB) and hepatitis B, because Infliximab can reactivate these infections if they are dormant in your body. You should not start Infliximab if you have an active, serious infection of any kind.

What are the serious risks of Infliximab?

Infliximab can increase the risk of serious infections (including reactivation of TB or hepatitis B), infusion reactions including severe allergic reactions, and, rarely, lymphoma or other cancers, worsening heart failure, nerve problems, and a lupus-like syndrome. Tell your doctor immediately about fever, persistent infection, unusual bruising or bleeding, chest pain, shortness of breath, numbness or weakness, or yellowing of the skin or eyes while on Infliximab.

Is Infliximab safe during pregnancy or breastfeeding?

Infliximab can cross the placenta, particularly later in pregnancy, and may remain in the baby's blood for months after birth, which can affect the timing of the baby's live vaccines. Infliximab should be used in pregnancy only if clearly needed and the benefit outweighs the potential risk, and a doctor should always be consulted. Only small amounts are expected in breast milk, but breastfeeding should also be discussed with your physician before use.

Can children receive Infliximab?

Yes, Infliximab is approved for children 6 years and older with moderate-to-severe Crohn's disease or ulcerative colitis, using the same weight-based dosing schedule as adults for those conditions. It has not been established as safe and effective for younger children or for other indications like rheumatoid arthritis or psoriasis in children.

Disclaimer

The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.

DoctorBlogArticles